Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Mar 24, 2023
TickeronGET DAILY SIGNALS
POINT Biopharma Global Inc. (PNT, $6.81) is expected to report earnings to fall+70% to -26 cents per share on March 24

POINT Biopharma Global Inc. (PNT, $6.81) is expected to report earnings to fall+70% to -26 cents per share on March 24

POINT Biopharma Global Inc. (PNT) is a clinical-stage pharmaceutical company that focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. The company is set to report its earnings on March 24, and analysts are expecting a significant drop in earnings per share. According to analysts' estimates, the company's earnings per share are expected to fall by 70% to -26 cents per share.

This news follows the company's last earnings report on September 30, which showed earnings per share of -86 cents, missing the estimate of -28 cents. This miss in earnings was likely due to the high costs associated with research and development, which is typical for a clinical-stage pharmaceutical company.

Looking at the company's valuation metrics, we can see that the P/B ratio is normal, sitting around the industry mean of 21.747. The P/E ratio of 0.000 is within average values for comparable stocks, averaging 125.520. The projected growth (PEG ratio) of 0.000 is also within normal values, averaging 3.734. However, the company does not pay a dividend, settling around the average of 0.028 among similar stocks. The P/S ratio of 0.000 is also within normal values, averaging 303.071.

Currently, with 607.70K shares outstanding, the company's market capitalization sits at 722.61M.

Despite these metrics, the stock has been in a downward trend, falling for three consecutive days on March 23, 2023. This trend is viewed as bearish, and investors should keep an eye on this stock for future declines. According to data from situations where PNT declined for three days, in 116 of 145 cases, the price declined further within the following month. Therefore, the odds of a continued downward trend are 80%.

We invite you to check out our premium products -- they’ll help you be best prepared to take on the market. One of the premium products that might be helpful for a new trader is the AI Pattern Search Engine. For a continuing trader, AI Real Time Patterns and our Screener, are a great way to pinpoint exactly what you’re looking for and to monitor the securities for an extended period of time.   

Related Ticker: PNT

Contributor

Dem Sem's AvatarDem Sem|Expert

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
4850 West 78th Street
Phone
+1 647 812-2417
Employees
129
Web
https://www.pointbiopharma.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.